|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
08037 CH BIOTECH SER
Nominal 
0.480 0.000 (0.000%) | 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | |
| Turnover | 211,985 | -88.551% | 1,851,532 | 623,761 | 655,792 | 59,214 |
| Cost of Sales | (177,661) | -76.330% | (750,575) | (265,741) | (316,710) | (36,841) |
| Gross Profit | 34,324 | -96.882% | 1,100,957 | 358,020 | 339,082 | 22,373 |
| 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | (16,186) | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 9,795 | -48.693% | 19,091 | (31) | 10,733 | (27,963) | |
| Profit / (Loss) on Disposal | (28) | -- | 1,696 | -- | (1,948) | (316) | |
| Other Non-operating Items | -- | -- | (3,707) | (2,687) | -- | 8,096 | |
| Share of Results of Asso. & JCEs | (7,678) | 83.684% | (4,180) | 0 | 0 | (1,390) | |
| Profit / (Loss) before Taxation | (142,025) | -- | 862,826 | 180,668 | 202,802 | (109,593) | |
| Taxation | 1,319 | -- | (157,258) | (48,096) | (35,179) | 2,110 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 45,259 | -- | (447,481) | (113,187) | (137,453) | 8,638 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (95,447) | -- | 258,087 | 19,385 | 30,170 | (98,845) | |
| 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | |
| Net Finance Costs / (Income) | 1,569 | -53.052% | 3,342 | 6,531 | 6,477 | 1,503 |
| Depreciation & Amortisation | 55,580 | -16.296% | 66,401 | 68,112 | 40,336 | 20,201 |
| Directors' Emoluments | 9,250 | -39.939% | 15,401 | 11,624 | 19,466 | 15,153 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -9.900 | -- | 26.800 | 2.000 | 3.100 | -10.300 |
| DPS (cts) | 0.000 | -- | 1.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | 3.731% | -- | -- | -- |
| Cash flow per share ($) | 0.203 | -- | 0.501 | 0.042 | 0.436 | (0.032) |
| NBV per share ($) | 0.480 | -- | 0.626 | 0.410 | 0.355 | 0.298 |
| Remarks: | Real time quote last updated: 27/12/2024 15:29 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders ($) | HKD -79,917,000 |
| %Change | 162.160% |
| EPS / (LPS) | HKD -0.083 |
| NBV Per Share ($) | HKD 0.405 |